Literature DB >> 88368

Interaction of vasoactive intestinal peptide with isolated intestinal epithelial cells from rat. 2. Characterization and structural requirements of the stimulatory effect of vasoactive intestinal peptide on production of adenosine 3':5'-monophosphate.

M Laburthe, J C Prieto, B Amiranoff, C Dupont, D Hui Bon Hoa, G Rosselin.   

Abstract

Porcine vasoactive intestinal peptide stimulated adenosine 3':5'-monophosphate (cyclic AMP) production in rat intestinal epithelial cells. The stimulation was dependent on time and temperature and was potentiated by the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine. Under optimal conditions (at 15 degrees C, with 0.2 mM 3-isobutyl-1-methylaxanthine, at a cell concentration up to 18 microgram DNA/ml), the cyclic AMP production produced by vasoactive intestinal peptide was constant for 10 min and stopped after 15 min incubation, at either low (1 nM) or high (30 nM) concentration of the peptide. This plateau effect was demonstrated not to be due to an inactivation of vasoactive intestinal peptide in the medium nor to an alteration of receptors for the peptide. Cyclic AMP production was sensitive to a concentration as low as 0.1 nM vasoactive intestinal peptide. Maximal stimulation of cyclic AMP levels by vasoactive intestinal peptide was observed with 30 nM vasoactive intestinal peptide and represented an 11-fold increased above basal. The dorse-response curve was monophasic with a Km of 2.3 x 10(-9) M. No cooperative effects were detected by Hill analysis. The positive non-linear relationship observed between stimulation of cyclic AMP production and occupancy of binding site was not time-dependent as indicated by experiments performed after 15, 45 and 120 min incubation. Maximal and half-maximal responses were obtained at about 70% and 7% occupation of binding sites, respectively. Chicken vasoactive intestinal peptide and porcine secretin were agonists of porcine vasoactive intestinal peptide with a 6-times and a 120-times lower potency, respectively. Among secretin analogs that were found to have low affinity for vasoactive intestinal peptide binding sites, [4-alanine, 5-valine]secretin, that resembles vasoactive intestinal peptide at the first seven amino acids at the N-terminal end, was a partial agonist of vasoactive peptide at the first seven amino acids at the N-terminal end, was a partial agonist of vasoactive intestinal peptide and others failed to stimulate cyclic AMP production. Glucagon (10microM), gastric inhibitory peptide (0.1 microM), substance, P, neurotensin, octapeptide of cholecystokinin, bovine pancreatic polypeptide, human gastrin I with leucine at residue 15, Leu-enkephalinand somatostatin (1 microM) did not alter cyclicAMP levels. Non-peptide mediators such as dopamine, serotonin, acetylcholine and histamine, tested at 10 microM, were also ineffective. Prostaglandins E2, E1 and isoproterenol, tested at 10 microM, induced an increase of cyclic AMP levels above basal but were 9.5, 13.7 and 17.5 times less efficient than vasoactive intestinal peptide, respectively. Thus vasoactive intestinal peptide is a unique stimulus of cyclic AMP production in rat intestinal epithelial cells.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 88368     DOI: 10.1111/j.1432-1033.1979.tb13034.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  16 in total

1.  Effect of vasoactive intestinal peptide on cyclic adenosine monophosphate production in enterocytes isolated from human duodenal biopsy specimens.

Authors:  J A Smith; M Griffin; S E Mireylees; R G Long
Journal:  Gut       Date:  1990-12       Impact factor: 23.059

2.  Photoaffinity labelling of the vasoactive-intestinal-peptide-binding site on intact human colonic adenocarcinoma cell line HT29-D4. Synthesis and use of photosensitive vasoactive-intestinal-peptide derivatives.

Authors:  J M Martin; H Darbon; J Luis; A el Battari; J Marvaldi; J Pichon
Journal:  Biochem J       Date:  1988-03-15       Impact factor: 3.857

3.  Evidence for the presence of insulin binding sites in isolated rat intestinal epithelial cells.

Authors:  M E Forgue-Lafitte; M R Marescot; M C Chamblier; G Rosselin
Journal:  Diabetologia       Date:  1980-10       Impact factor: 10.122

4.  Vasoactive intestinal peptide induces the synthesis of the cholesterol side-chain cleavage enzyme complex in cultured rat ovarian granulosa cells.

Authors:  W H Trzeciak; C E Ahmed; E R Simpson; S R Ojeda
Journal:  Proc Natl Acad Sci U S A       Date:  1986-10       Impact factor: 11.205

5.  Short-term regulation of glycolysis by vasoactive intestinal peptide in epithelial cells isolated from rat small intestine.

Authors:  I Rossi; L Monge; J E Feliu
Journal:  Biochem J       Date:  1989-09-01       Impact factor: 3.857

6.  The rat liver vasoactive intestinal peptide binding site. Molecular characterization by covalent cross-linking and evidence for differences from the intestinal receptor.

Authors:  A Couvineau; M Laburthe
Journal:  Biochem J       Date:  1985-01-15       Impact factor: 3.857

7.  Preferential binding of vasoactive intestinal polypeptide to basolateral membrane of rat and rabbit enterocytes.

Authors:  K Dharmsathaphorn; V Harms; D J Yamashiro; R J Hughes; H J Binder; E M Wright
Journal:  J Clin Invest       Date:  1983-01       Impact factor: 14.808

8.  Binding of Escherichia coli heat-stable enterotoxin to rat intestinal cells and brush border membranes.

Authors:  J C Frantz; L Jaso-Friedman; D C Robertson
Journal:  Infect Immun       Date:  1984-02       Impact factor: 3.441

9.  Role of cyclic nucleotides and calcium in the nutrient-induced release of cholecystokinin-like immunoreactivity in rats.

Authors:  J C Cuber; S Aucouturier; C Bernard; J A Chayvialle
Journal:  J Physiol       Date:  1992-04       Impact factor: 5.182

10.  Importance of the vasoactive intestinal peptide receptor in the stimulation of cyclic adenosine 3',5'-monophosphate in gallbladder epithelial cells of man. Comparison with the guinea pig.

Authors:  C Dupont; J P Broyart; Y Broer; B Chenut; M Laburthe; G Rosselin
Journal:  J Clin Invest       Date:  1981-03       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.